{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:51:14Z","timestamp":1793249474242,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Brucellosis is an endemic disease present in many countries worldwide, but it is rare in Europe and North America. Nevertheless brucella is included in the bacteria potentially used for bioterrorism. The aim of this study was the investigation of the antibiotic susceptibility profile of brucella isolates from areas of the eastern Mediterranean where it has been endemic.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The susceptibilities of 74 Brucella melitensis isolates derived from clinical samples (57) and animal products (17) were tested in vitro. The strains originate from Crete (59), Cyprus (10), and Syria (5). MICs of tetracycline, rifampicin, streptomycin, gentamicin, norfloxacin, ciprofloxacin, levofloxacin, trimethoprim\/sulfamethoxazole, ampicillin, amoxicillin\/clavulanic acid, and erythromycin were detected by E-test method. The NCCLS criteria for slow growing bacteria were considered to interpret the results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>All the isolates were susceptible to tetracycline, streptomycin, gentamicin, ciprofloxacin, norfloxacin, and levofloxacin. Two isolates presented reduced susceptibility to rifampicin (MIC value: 1.5 mg\/l) and eight to SXT (MIC values: 0.75\u20131.5 mg\/l). Erythromycin had the highest (4 mg\/l) MIC<jats:sub>90<\/jats:sub>value and both norfloxacin and erythromycin the highest (1.5 mg\/l) MIC<jats:sub>50<\/jats:sub> value.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Brucella isolates remain susceptible in vitro to most antibiotics used for treatment of brucellosis. The establishment of a standardized antibiotic susceptibility method for <jats:italic>Brucella spp<\/jats:italic> would be useful for resistance determination in these bacteria and possible evaluation of bioterorism risks.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1476-0711-5-24","type":"journal-article","created":{"date-parts":[[2006,10,3]],"date-time":"2006-10-03T06:26:13Z","timestamp":1159856773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics"],"prefix":"10.1186","volume":"5","author":[{"given":"Aun","family":"Turkmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Ioannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasia","family":"Christidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Psaroulaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feidias","family":"Loukaides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiannis","family":"Tselentis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,10,2]]},"reference":[{"key":"91_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1473-3099(06)70382-6","volume":"6","author":"G Pappas","year":"2006","unstructured":"Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV: The new global map of human brucellosis. Lancet Infect Dis. 2006, 6: 91-99. 10.1016\/S1473-3099(06)70382-6","journal-title":"Lancet Infect Dis"},{"issue":"9(12)","key":"91_CR2","first-page":"E15","volume":"15","author":"P Bossi","year":"2004","unstructured":"Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J, Werner A, Maidhof H, Gouvras G, Task Force on Biological and Chemical AgentsThreats, Public Health Directorate, European Commission, Luxembourg : Bichat guidelines for the clinical management of brucellosis and bioterrorism-related brucellosis. Euro Surveill. 2004, 15 (9(12)): E15-16.","journal-title":"Euro Surveill"},{"key":"91_CR3","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMra050570","volume":"352","author":"G Pappas","year":"2005","unstructured":"Pappas G, Akritidis N, Bosilkovski M, Tsianos E: Brucellosis. N Engl J Med. 2005, 352: 2325-2336. 10.1056\/NEJMra050570","journal-title":"N Engl J Med"},{"issue":"3","key":"91_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/clinids\/13.3.524","volume":"13","author":"WH Hall","year":"1991","unstructured":"Hall WH: Modern chemotherapy for brucellosis in humans. Rev Infect Dis. 1991, 13 (3): 523-524.","journal-title":"Rev Infect Dis"},{"key":"91_CR5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1128\/AAC.35.4.756","volume":"35","author":"JA Garcia-Rodriguez","year":"1991","unstructured":"Garcia-Rodriguez JA, Garcia-Sanchez JE, Trujillano I: Lack of effective bactericidal activity of new quinolones against Brucella spp. Antimicrob Agents Chemother. 1991, 35: 756-759.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"91_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000239353","volume":"41","author":"SM Qadri","year":"1995","unstructured":"Qadri SM, Halim MA, Ueno Y, Abumustafa FM, Postle AG: Antibacterial activity of azithromycin against Brucella melitensis. Chemotherapy. 1995, 41 (4): 253-256.","journal-title":"Chemotherapy"},{"key":"91_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ijantimicag.2003.09.024","volume":"23","author":"N Baykam","year":"2004","unstructured":"Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B: In vitro antimicrobial susceptibility of Brucella species. Intern J Antimicrob Agents. 2004, 23: 405-407. 10.1016\/j.ijantimicag.2003.09.024.","journal-title":"Intern J Antimicrob Agents"},{"key":"91_CR8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1080\/00365540410020767","volume":"36","author":"A Lopez-Merino","year":"2004","unstructured":"Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R, Orrantia-Gradin R, Hernandez-Oliva GM, Guttierrez-Rubio AT, Cardenosa O: Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis. 2004, 36: 636-638. 10.1080\/00365540410020767","journal-title":"Scand J Infect Dis"},{"key":"91_CR9","volume-title":"Eighth informational supplement. NCCLS document M 100-S8","author":"National Committee for Clinical Laboratory Standards","year":"1998","unstructured":"National Committee for Clinical Laboratory Standards : Performance standards for antimicrobial susceptibility testing. Eighth informational supplement. NCCLS document M 100-S8. 1998, 18: Wayne, PA"},{"key":"91_CR10","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1128\/JCM.42.12.5439-5443.2004","volume":"42","author":"C Marianelli","year":"2004","unstructured":"Marianelli C, Ciuchini F, Tarantino M, Pasquali P, Adone R: Genetic bases of the rifampin resistance phenotype in Brucella spp. J Clin Microbiol. 2004, 42: 5439-5443. 10.1128\/JCM.42.12.5439-5443.2004","journal-title":"J Clin Microbiol"},{"key":"91_CR11","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1128\/AAC.35.9.1925","volume":"35","author":"E Rubinstein","year":"1991","unstructured":"Rubinstein E, Lang R, Shasha B, Hagar B, Diamanstein L, Joseph G, Anderson M, Harrison K: In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother. 1991, 35: 1925-1927.","journal-title":"Antimicrob Agents Chemother"},{"key":"91_CR12","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1128\/AAC.37.9.1831","volume":"37","author":"M Akova","year":"1993","unstructured":"Akova M, Uzun O, Akalin HE, Hayran M, Unal S, Gur D: Quinolones in the treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. J Antimicrob Chemother. 1993, 37: 1831-1834.","journal-title":"J Antimicrob Chemother"},{"key":"91_CR13","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1128\/AAC.43.9.2337","volume":"43","author":"D Gur","year":"1999","unstructured":"Gur D, Kocagoz S, Akova M, Unal S: Comparison of E test to Microdilution for determining of in vitro activities of antibioticsagainst Brucella melitensis. Antimicrob Agents Chemother. 1999, 43: 2337-","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"91_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000088122","volume":"14","author":"T Yamazham","year":"2005","unstructured":"Yamazham T, Aydemir S, Tunger A, Serter D, Gokengin D: Invitro activities of various antimicrobials against Brucella melitensis strains in the Aegean region in Turkey. Med Princ Pract. 2005, 14 (6): 413-416. 10.1159\/000088122","journal-title":"Med Princ Pract"},{"issue":"5","key":"91_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/00365540310008348","volume":"35","author":"H Bodur","year":"2003","unstructured":"Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Colpan A, Erbay A: Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis. 2003, 35 (5): 337-338. 10.1080\/00365540310008348","journal-title":"Scand J Infect Dis"},{"issue":"6","key":"91_CR16","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000088960","volume":"51","author":"S Al Dakour","year":"2005","unstructured":"Al Dakour S, Hagen RM, Nockler K, Tomaso H, Witting M, Scholz HC, Vergnaud G, Neubauer H: Failure of a short-term antibiotic therapy for human brucellosis using ciprofloxacin. A study on in vitro susceptibility of Brucella strains. Chemotherapy. 2005, 51 (6): 352-356. 10.1159\/000088960","journal-title":"Chemotherapy"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-0711-5-24.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:31:19Z","timestamp":1630449079000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/1476-0711-5-24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["91"],"URL":"https:\/\/doi.org\/10.1186\/1476-0711-5-24","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"5 July 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"24"}}